穿刺技术的改进和创新是穴位埋线疗法的第三次飞跃

穴位埋线是长效针灸,是在传统针具和针法基础上建立和发展起来的,是针灸技术的发展和延伸,穴位埋线的核心技术是穿刺技术,穴位埋线的三大要素中,针具、埋藏物、穿刺技巧之间是互相影响、互相促进的。针具的改进成功实现了穴位埋线疗法的第一次飞跃,埋藏物的改进成功实现了穴位埋线疗法的第二次飞跃,穿刺技术的改进和创新是穴位埋线疗法的第三次飞跃。     

诊断幽门螺杆菌感染的新进展

目前幽门螺杆菌感染的检测方法分为侵性检查和非侵入性检查,前者包括：培养,组织学检查,快速尿素酶试验,ＰＣＲ;后者包括：＾１３Ｃ／＾１４Ｃ－尿素呼吸试验及＾１５Ｎ尿氨排泄试验,血清学,尽管检测方法较多,但在临床和科研中,由于使用目的的不同,选择的检测方法有区别。     

左氧氟沙星滴眼液及眼用凝胶的研究概述

目的 对近年来左氧氟沙星在眼用制剂方面的研究作一综述。方法 参考及整理有关文献。结果 总结并归纳了左氧氯沙星滴眼及眼用凝胶的研究进展。结论：左氧氟沙星缓释型眼用制剂越来越受到重视和发展，并具有广泛的临床应用前景。     

美国临床肿瘤学会年度报告——2005年临床肿瘤学进展

2005年临床肿瘤学进展是由美国临床肿瘤学会（the American Society of Clinical Oncology，ASCO）发布的第一份关于各类肿瘤在治疗、筛查和预防方面最重要进展的独立年度报告。展示了2005年各种肿瘤的主要临床研究进展。     

阻塞性睡眠呼吸暂停低通气综合征患者听力学损害研究进展

阻塞性睡眠呼吸暂停低通气综合症(obstructive sleep apnea hypopnea syndrome,OSAHS)是一种常见的睡眠障碍性疾病,长期的呼吸暂停和低通气可引起不同程度的低氧血症及高碳酸血症,继发组织缺氧,最终导致多器官功能损害,其中包括第8对颅神经-听神经的损害.临床观察中也发现了部分OSAH...     

Src激酶家族与紫杉醇耐药相关性的研究进展

Src激酶家族(SFK)在许多恶性肿瘤中均有高表达,对于肿瘤细胞的恶性行为具有广泛的调节作用。紫杉醇是临床上广泛应用的化疗药物,但由于耐药性的出现使其疗效逐渐下降。本文就SFK的结构与调节方式、紫杉醇耐药产生的分子机制以及SFK调节紫杉醇耐药的研究进展进行综述,以期为基于紫杉醇的肿瘤治疗方案提供新的治疗参考依据。     

2011年临床肿瘤学重大进展——美国临床肿瘤学会年度报告

美国临床肿瘤学会（American Society of Clinical Oncology，ASCO）每年都会对过去一年在肿瘤研究上具有最深远影响的进展进行回顾。2011年，我们纳入了54项最有意义的研究，其中12项属于重大进展。     

癌性疲劳的相关研究进展

过去的几十年中,化疗药物所引起的副反应对肿瘤患者产生的影响一直以疼痛最为明显,近年来随着吗啡、芬太尼制剂等止痛药物的广泛应用,这一主诉对患者的影响逐渐下降,而疲劳感对肿瘤患者的影响逐渐凸显出来.本文旨在对癌性疲劳（cancer-related fatigue,CRF）的相关研究进展作一综述.     

What has happened in the last 50 years in immunology

Fifty years ago, in 1964, our understanding of the immune system was very rudimentary. Gell and Coombs had just described classes of hypersensitivity reactions, and Bruton had described and commenced immunoglobulin replacement in agammaglobulinaemia. The distinction between T and B cells was not identified and characterised until the 1960s and 1970s. This was followed by increasing recognition of T and B cell collaboration in immune responses and identification of significant immunodeficiencies. CD4 and CD8 T cells were only recognised in the 1970s and 1980s. We now know of five CD4 subsets; dysfunction of each is associated with different disorders. By 2014, advances in technology have enabled identification of the genetic basis of over 240 primary immunodeficiencies. Research into the gut microbiome and vitamin D holds promise for the understanding, treatment and prevention of autoimmune and allergic diseases. Immunoglobulin preparations for the treatment of antibody deficiencies improved with the development of preparations for intravenous then subcutaneous administration, giving patients choice and the ability for home‐based treatment, especially if experiencing infusion associated adverse effects. Newborn screening for severe combined immunodeficiency is a reality. Improvements in haemopoietic stem cell transplantation and now gene therapy, albeit still only available in the research setting, are improving long‐term survival in primary immunodeficiencies. Biologic therapeutic agents are improving the control of autoimmune disease but potentially leading to secondary immunodeficiency, increasing the risk of opportunistic infection and malignancy. It is an exciting time.     

Management of systemic lupus erythematosus in the coming decade: potentials and challenges

The management of systemic lupus erythematosus (SLE) has improved in the past 50 years, but there is still a 3–5‐fold increased mortality compared to the general population, with major organ failure due to active disease, infection and cardiovascular disease as the major challenges for the coming decade. Research advances at cellular, molecular and genetic levels enhance our understanding of the immunopathogenic mechanisms of SLE, leading to the development of drugs targeting specific sites of immune dysregulation – with therapies directed at cytokines, B‐ and T‐cells, and their interactions showing promise. Advances are expected in the field of haematopoietic stem cell transplant (HSCT) as a therapeutic option for a subset of patients. Furthermore, some non‐traditional immunomodulating therapies like statins, leflunomide and tacrolimus may prove useful as alternative or adjunct treatment in some patients. A better understanding of how current immunosuppressants act at the cellular and molecular level should guide the re‐evaluation of the indications, doses and duration of therapy in clinical trials using these agents, many of which have not been subjected to proper double‐blinded placebo‐controlled studies. Research on triggers of SLE onset and flare of activity continues to yield information helpful in prevention. The evidence on the impact of psychosocial and economic factors on the outcome of SLE is overwhelming and the rheumatology community should enlist the assistance of other healthcare professionals, patient advocates and local health authorities to address these issues pertinent to good patient care and outcome.